All Columns articles
-
OpinionNon-hallucinogenic psychedelics
Chemical insights and advances are contributing to a new therapeutic avenue for mental health conditions
-
OpinionSafety is everyone’s responsibility
Maintaining culture and investment is key, especially in the absence of incidents
-
OpinionIgnoring women’s health shouldn’t be an option
Developing therapies for conditions that predominantly affect women is a neglected, but enormous, opportunity
-
OpinionWomen are not just another confounding factor in drug development
Ignoring physiological differences between the sexes is indefensible
-
OpinionRebuilding pharma supply chains
Multinationals are promising huge US investments, but it’s not all because of Trump’s policies
-
OpinionIran port explosion highlights issues of shipping hazardous chemicals
Intersecting regulations and jurisdictions mean rules can be accidentally or deliberately overlooked
-
OpinionIn search of truth and rules
To codify and predict ever more complex phenomena is one of science’s great drivers
-
OpinionQuality research under threat as budgets are being squeezed
Researchers are once again being asked to turn less into more
-
OpinionGiving companies room to grow
Can shopping centres and offices become urban lab spaces for innovative companies to grow and scale-up?
-
OpinionPolymorphs matter – especially when they might disappear
Disappearing polymorphs offer a fascinating example of the dark arts of crystallisation
-
BusinessAcceptable levels of (epi)genetic engineering
Amplifying or silencing genes may be preferable to permanently changing genetic code
-
OpinionTrump’s tariff stand-off
Piling cost and complexity to stretched global supply chains will hit industries hard
-
-
OpinionWelcome to the MegaPharm target selection and project resourcing meeting
Overheard recently in a seminar room near you…
-
NewsThey break it, we all pay for it
GK Chesterton’s legacy goes beyond his Father Brown detective novels and explains why tearing down institutions harms us all
-
OpinionGetting into the weeds of the glyphosate debate
Assessments of the risk posed by the controversial herbicide depend on how the evidence is weighed
-
BusinessUS reviews chemical incident prevention planning rules
Risk Management Program has been extended and rolled back under successive governments
-
OpinionWeight loss drug supply races
With official shortages ended, but the first generics gearing up for launch, companies are looking for the next generation of drugs
-
OpinionClassifications, racial discrimination and Covid-19
Lessons with philosophical significance for how we group people and objects
-
OpinionChemists amid coronavirus five years on
Rebecca Trager catches up with four chemists to see how their working lives have changed since the start of the Covid-19 pandemic